Opportunities and challenges in open access publishing of industry-sponsored research
Medical Publishing Insights and Practices (MPIP) initiative members share perspectives on the benefits of publishing industry-sponsored research open access.
Are standards required for preprint publishing platforms?
A recent BMJ editorial discusses the benefits and risks of the use of preprints during the current coronavirus pandemic.
Open access publishing of pharma-sponsored research: insights from a Scientific Publications Lead
Slávka Baróniková shares her opinions on open access publishing and suggests how this can be successfully achieved within pharma.
As science looks to adapt to the COVID-19 pandemic, the need to publish with transparency, speed and openness is ever greater
The increasing range of publication choices and demand for open access are explored in this sponsored article from Taylor & Francis Group.
Steps to reduce bias in systematic review protocols
Systematic reviews are generally considered gold standard evidence in healthcare, but a founding member of Cochrane believes steps can be taken to increase transparency and reduce bias in their protocols.
Journal open access cost breakdowns will be needed for cOAlition S support
From 2022, journals will need to follow cOAlition S price transparency requirements to get paid. Find out more about the frameworks and potential benefits here.
SPENT: new guidelines for reporting n-of-1 trial protocols
An extension and elaboration of the SPIRIT checklist specific to n-of-1 trials aims to improve the quality and reporting of protocols for this trial type.
Will standardised research data policies make publishing more FAIR?
The Research Data Alliance has published standardised research data policies, but wider collaboration is needed to ensure they are supported and implemented.
[VIDEO]: How to disclose relationships, activities, and potential conflicts of interest
Tips on disclosures of interest from the Medical Publishing Insights and Practices Initiative (MPIP).
Reporting of many clinical trials ruled illegal
A US court ruling finds reporting of many clinical trials of unapproved drugs in breach of the law. But responses to the ruling are uncertain.
Peer review research needs improved collaboration and infrastructure
A recent article in Nature reveals how dedicated data sharing infrastructure may be key to facilitating systematic research into peer review processes.
Ghostwriting in peer review: should journals recognise non-invited co-reviewers?
With a survey revealing that half of researchers have ghostwritten peer review reports, do peer review processes require reform?
The TOP Factor: a new journal metric to assess transparency and reproducibility policies
Find out more about the TOP Factor, an alternative metric to the impact factor, evaluating academic journals based on open science policies.
COVID-19: ISMPP issues guidance regarding authorship challenges
Find out more about ISMPP’s guidance for navigating author non-responsiveness in the wake of the coronavirus pandemic.
Improving transparency in the reporting of systematic reviews without meta-analysis
Find out why guidance is needed and what’s covered in the new Synthesis Without Meta-analysis (SWiM) guidelines.
Is preregistering scientific research becoming mainstream?
PLOS ONE now offers Registered Reports, shifting peer review focus from results to the quality of study design. Is this part of the future of open science?